US Oncology, Inc., the nation's leading integrated oncology company, announced today that two physicians affiliated with US Oncology Research will be honored at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 4 - 8 at McCormick Place in Chicago.Daniel D. Von Hoff, MD, FACP, is the recipient of the 2010 David A. Karnofsky Memorial Award and Lecture for his outstanding achievements in cancer research and for his impact on the treatment of patients with cancer. Dr. Von Hoff is an internationally recognized physician-scientist who has contributed to the development of numerous anticancer agents, including paclitaxel, docetaxel, irinotecan and gemcitabine. He currently serves as physician-in-chief for the Translational Genomics Institute in Phoenix, Arizona, chief scientific officer at US Oncology and Scottsdale Healthcare, and clinical professor of medicine at The University of Arizona College of Medicine. Dr. Von Hoff also serves as lead physician of the Translational Oncology Program (TOP) for US Oncology. The TOP program offers Phase I clinical trial studies, which often offer first-in-human agents. He is also responsible for bringing many new compounds to US Oncology Research for studies.
John V. Cox, DO, FACP, Texas Oncology is a recipient of the ASCO Statesman Award. This award recognizes ASCO members for their extraordinary volunteer service, dedication, and commitment to ASCO. Recipients of the 2010 Statesman Award have given 20 years of volunteer service.
In addition, more than 50 physicians affiliated with US Oncology Research and the United Network of US Oncology participated in studies that will be presented in oral and poster presentations at this year's ASCO. US Oncology Research has a long history of bringing innovative and successful agents to market. To date, US Oncology Research has played a role in the development of 40 FDA approved cancer fighting therapies.
Presentations that US Oncology affiliated physicians are part of include:...
Karen L. Tedesco, MD, New York Oncology Hematology - Amsterdam
Joanne L. Blum, MD, PhD, Texas Oncology - Baylor Sammons Cancer Center
Cynthia R. Osborne, MD, Texas Oncology - Baylor Sammons Cancer Center
Frankie Ann Holmes, MD, Texas Oncology - Houston Memorial City
Poster #21G Saturday, June 05, 2:00 PM - 6:00 PM S Hall A2
-- A phase II trial of trabectedin (T) in patients (pts) with HER2-
positive and BRCA1/2 germ-line-mutated metastatic breast cancer
(MBC).
...
